Market Cap
$12.1B
BAX
BAXTER INTERNATIONAL INC
$23.76 ▲ +0.51%
Prev close $23.64Market cap$12.1B
ConsensusSell
12-mo target$28.73 (+20.9%)
▼ Bearish
Analyst conviction 3/10
High Impact Filing (7/10)40 New Institutional Positions10 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on BAX right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Sell (25%)
Inst. Holders
50 funds
Inst. Value
$10.1B
Inst. Activity
40 buys / 10 sells
Social Sentiment
50° Neutral
SEC Reports
12
Congressional
3 trades
Price chart 30d -7.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 short_volume
Short Volume: BAX — 62.1% short (1.8M / 3.0M)
Short: 1,848,634 | Exempt: 78 | TRF Vol: 2,979,212 | Short Ratio: 62.1% | Off-exchange volume (dark
Sep 29, 2026 Event
Baxter v. PDD Holdings Inc. et al
Court ruling (nyed) — Docket: 1:24-cv-05653
Sep 16, 2026 Event
Dextrose Injection, USP, 70 %, 2000 mL bags, Rx Only, Baxter Healthcare Corporation Deerfield, IL, 60016, Made in USA, NDC 00338-0719-06
Class I: Presence of Particulate Matter: particulate matter identified as stainless steel particles
Sep 2, 2026 Insider
Hider Andrew P. surrendered for taxes 54,276 shares
President and CEO @ $25.70 ($1.4M)
Sep 2, 2026 Insider
Foster Julie surrendered for taxes 2,098 shares
President, Front Line Care @ $25.70 ($53.9K)
Sep 1, 2026 Insider
Aug 19, 2026 SEC Teaff James surrendered for taxes 750 shares
President, CCS @ $25.48 ($19.1K)
Baxter appointed John Rogers as CFO, effective October 1, 2026, replacing departing interim CFO Anita Zielinski. The com
8-K — Impact 3/10
Baxter entered into Amendment No. 2 to its credit agreement, relaxing the net leverage ratio covenant for the next five
8-K — Impact 5/10
Analyst ratings buy % +212.5%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
25% rate it Buy or better · 20 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jul 31, 2026 | TD Cowen | MAINTAIN | Hold | 56% |
| Jul 31, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
| Jul 31, 2026 | Stifel | MAINTAIN | Hold | 54% |
| Jul 31, 2026 | Citigroup | UPGRADE | Neutral | 55% |
| Jul 28, 2026 | UBS | MAINTAIN | Neutral | 55% |
| Jul 28, 2026 | Stifel | MAINTAIN | Hold | 54% |
| Jul 27, 2026 | TD Cowen | MAINTAIN | Hold | 56% |
| Jul 15, 2026 | Goldman Sachs | MAINTAIN | Neutral | 54% |
| Jul 6, 2026 | Evercore ISI Group | MAINTAIN | Outperform | 59% |
| May 28, 2026 | Citigroup | DOWNGRADE | Sell | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 1 | 4 | 14 | 1 | 0 | 25% | |
| Aug 1, 2026 | 1 | 4 | 14 | 1 | 0 | 25% | |
| Jul 1, 2026 | 0 | 2 | 15 | 5 | 2 | 8% | |
| Jun 1, 2026 | 0 | 1 | 16 | 5 | 2 | 4% | |
| May 1, 2026 | 1 | 4 | 16 | 1 | 0 | 23% | |
| Apr 1, 2026 | 1 | 4 | 16 | 1 | 0 | 23% | |
| Mar 1, 2026 | 1 | 4 | 16 | 1 | 0 | 23% | |
| Feb 1, 2026 | 0 | 2 | 16 | 6 | 1 | 8% |
Price targets
Where 11 covering analysts think BAX trades over the next 12 months.
$28.73 +20.9% upside Strong Buy
Current$23.76 Low$23.00 Median$28.00 High$40.00 11 analysts
$23.00$40.00
Analyst rating Hold· 2.7/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
12 SEC filing reports analyzed · 3 bullish, 1 bearish, 2 mixed, 6 neutral · avg impact 4.3/10.
NEUTRAL8-K3/10
Baxter appointed John Rogers as CFO, effective October 1, 2026, replacing departing interim CFO Anit
Aug 19, 2026
MIXED8-K5/10
Baxter entered into Amendment No. 2 to its credit agreement, relaxing the net leverage ratio covenan
Aug 18, 2026
BULLISHINST-CLUSTER4/10
11 institutional buyers accumulated $9.2M in new BAX positions during Q2 2026, while 3 sellers reduc
Aug 12, 2026
NEUTRAL8-K4/10
Baxter announced cash tender offers to purchase up to $500 million aggregate principal amount of its
Aug 4, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 30, 2026
Clinical Trial
Comparing Efficacy of Tea Tree Oil Versus Topical Azithromycin in Treating Dry Eye
Phase Phase 2 — COMPLETED
Sep 30, 2026
short_volume
Short Volume: BAX — 62.1% short (1.8M / 3.0M)
Short: 1,848,634 | Exempt: 78 | TRF Vol: 2,979,212 | Short Ratio: 62.1% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
Enforcement
Baxter v. PDD Holdings Inc. et al
Court ruling (nyed) — Docket: 1:24-cv-05653
Sep 28, 2026
short_volume
Short Volume: BAX — 66.2% short (1.1M / 1.7M)
Short: 1,141,636 | Exempt: 1,435 | TRF Vol: 1,724,761 | Short Ratio: 66.2% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
Enforcement
Williams v. Baxter
Court ruling (nywd) — Docket: 1:25-cv-00579
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.52 | $0.50–$0.54 | -24.8% | +0.0% | 2↑ 7↓ | $2.9B | 11 |
| Next Q | $0.61 | $0.59–$0.65 | 39.3% | +0.0% | 1↑ 8↓ | $3.0B | 11 |
| Current FY | $2.05 | $1.97–$2.09 | -9.8% | +0.0% | 12↑ 0↓ | $11.6B | 13 |
| Next FY | $2.04 | $1.94–$2.12 | -0.5% | +0.0% | 11↑ 1↓ | $11.9B | 13 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.519 | — |
| 7d ago | $0.519 | — |
| 30d ago | $0.519 | — |
| 60d ago | $0.532 | -0.013 |
| 90d ago | $0.532 | -0.013 |
Institutional ownership
Which big funds own BAX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $10.1B total value (474,130,968 shares) as of 2026-Q2. Top holders: BlackRock,, PZENA, DODGE. Net buying activity: 40 institutions added/increased vs 10 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 81,842,105 | $1.7B | 17.3% | — |
| PZENA INVESTMENT MANAGEMENT LLC | 65,295,393 | $1.4B | 13.8% | — |
| DODGE & COX | 58,386,345 | $1.2B | 12.3% | — |
| FMR LLC | 53,913,831 | $1.1B | 11.4% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 33,754,280 | $719.6M | 7.1% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 24,057,190 | $512.9M | 5.1% | — |
| STATE STREET CORP | 20,600,468 | $439.4M | 4.3% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 14,123,689 | $300.6M | 3.0% | — |
| Invesco Ltd. | 12,361,881 | $263.6M | 2.6% | — |
| UBS Group AG | 9,529,309 | $203.2M | 2.0% | DOUBLED +120.6% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| UBS Group AG | DOUBLED | 4,319,497 | 9,529,309 | +120.6% | $203.2M |
| GOLDMAN SACHS GROUP INC | ADD | 3,869,555 | 7,150,462 | +84.8% | $152.4M |
| MARSHALL WACE, LLP | DOUBLED | 2,266,708 | 4,857,267 | +114.3% | $103.6M |
| NORGES BANK | NEW | — | 4,144,905 | — | $88.4M |
| Holocene Advisors, LP | NEW | — | 2,666,396 | — | $56.8M |
| JONES FINANCIAL COMPANIES LLLP | ADD | 1,476,265 | 2,406,207 | +63.0% | $53.0M |
| Artisan Partners Limited Partnership | NEAR_EXIT | 4,861,774 | 1,023,677 | -78.9% | $21.8M |
| Gotham Asset Management, LLC | DOUBLED | 361,688 | 862,123 | +138.4% | $18.4M |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | ADD | 625,803 | 840,121 | +34.2% | $17.9M |
| SEI INVESTMENTS CO | TRIM | 906,916 | 669,220 | -26.2% | $14.3M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
17 insiders, 41 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Hider Andrew P. | President and CEO | TAX W/H | 54,276 | $25.70 | $1.4M |
| Sep 2, 2026 | Foster Julie | President, Front Line Care | TAX W/H | 2,098 | $25.70 | $53.9K |
| Sep 1, 2026 | Teaff James | President, CCS | TAX W/H | 750 | $25.48 | $19.1K |
| Jun 2, 2026 | Wallace Steven P. | President, Adv. Surgery | TAX W/H | 153 | $18.68 | $2.9K |
| Jun 2, 2026 | Teaff James | President, CCS | TAX W/H | 321 | $18.68 | $6.0K |
| Jun 1, 2026 | Zielinski Anita A | SVP, Interim CFO, CAO & Cntrlr | AWARD | 13,426 | — | — |
| May 5, 2026 | Ampofo William A. II | Director | AWARD | 12,836 | — | — |
| May 5, 2026 | Craig Jeffrey A | Director | AWARD | 12,836 | — | — |
| May 5, 2026 | Shafer David Brent | Director | AWARD | 12,836 | — | — |
| May 5, 2026 | MORRISON PATRICIA | Director | AWARD | 12,836 | — | — |
Congressional trades
BAX trades disclosed by members of Congress, with disclosure delay.
1 members · 2 buys / 1 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | Michael McCaul | R | HOUSE | BUY | $15,001 - $50,000 | Baxter International Inc | Apr 10, 2026(19d) |
| Feb 17, 2026 | Michael McCaul | R | HOUSE | SELL | $100,001 - $250,000 | Baxter International Inc | Mar 12, 2026(24d) |
| Jan 13, 2026 | Michael McCaul | R | HOUSE | BUY | $50,001 - $100,000 | Baxter International Inc | Feb 12, 2026(31d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for BAX.
Shares short
23,227,313
Settlement Sep 15, 2026
Change vs prior
-0.3%
Semi-monthly cycle
Days to cover
4.5
At avg daily volume
Of shares outstanding
≈4.5%
Estimate — not % of float
All BAX filing & press-release reports (12)
- 8-K reportAug 19, 2026
- 8-K reportAug 18, 2026
- INST-CLUSTER reportAug 12, 2026
- 8-K reportAug 4, 2026
- 8-K reportJul 30, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 8, 2026
- 8-K reportApr 30, 2026
- DEFA14A reportApr 29, 2026
- COURT-RULING reportMar 27, 2026
- DEFA14A reportMar 23, 2026
- INST-CLUSTER reportFeb 28, 2026